Despite the widespread and growing use of GLP-1 RAs, particularly in diabetic patients with overweight or obesity [10], little is known about how these medications influence habitual dietary intake in real-world settings. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.